AID and APOBEC deaminases: Balancing DNA damage in epigenetics and immunity

Epigenomics

Volumn 6, Issue 4, 2014, Pages 427-443

  Franchini, Don Marc ^a   Petersen Mahrt, Svend K ^a  

^a FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

AID; APOBEC; deaminase; DNA demethylation; DNA repair; epigenetics; immunity

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; CYTOSINE DEAMINASE; DEAMINASE; IMMUNOGLOBULIN; CYTIDINE DEAMINASE; DNA BINDING PROTEIN; ONCOPROTEIN;

ADAPTIVE IMMUNITY; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CARCINOGENESIS; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; EPIGENETICS; HUMAN; IMMUNITY; INNATE IMMUNITY; NONHUMAN; REVIEW; SOMATIC HYPERMUTATION; TRANSPOSON; VIRUS INFECTION; ANIMAL; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; METABOLISM;

ANIMALS; CYTIDINE DEAMINASE; DNA DAMAGE; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; HUMANS; IMMUNITY; IMMUNOGLOBULINS; PROTO-ONCOGENE PROTEINS;

EID: 84908153041     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.35     Document Type: Review

References (184)

1. Lindahl T. Instability and decay of the primary structure of DNA. Nature 362(6422), 709-715 (1993).
2. Friedberg EC. DNA Repair And Mutagenesis. American Society for Microbiology, WA, USA (2005).
3. Neuberger MS, Harris RS, Di Noia J, Petersen-Mahrt SK. Immunity through DNA deamination. Trends Biochem. Sci. 28(6), 305-312 (2003).
4. Petersen-Mahrt S. DNA deamination in immunity. Immunol Rev. 203, 80-97 (2005).
5. Powell LM, Wallis SC, Pease RJ, Edwards YH, Knott TJ, Scott J. A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell 50(6), 831-840 (1987).
6. Teng B, Burant CF, Davidson NO. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 260(5115), 1816-1819 (1993).
7. Harris RS, Petersen-Mahrt SK, Neuberger MS. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell 10(5), 1247-1253 (2002).
8. Petersen-Mahrt SK, Harris RS, Neuberger MS. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 418(6893), 99-103 (2002).
9. Franchini DM, Schmitz KM, Petersen-Mahrt SK. 5-Methylcytosine DNA demethylation: more than losing a methyl group. Annu. Rev. Genet. 46, 419-441 (2012).
10. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002).
11. Di Noia JM, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. Annu. Rev. Biochem. 76, 1-22 (2007).
12. Alt FW, Zhang Y, Meng FL, Guo C, Schwer B. Mechanisms of programmed DNA lesions and genomic instability in the immune system. Cell 152(3), 417-429 (2013).
13. Peled JU, Kuang FL, Iglesias-Ussel MD et al. The biochemistry of somatic hypermutation. Annu. Rev. Immunol. 26, 481-511 (2008).
14. Stavnezer J, Guikema JE, Schrader CE. Mechanism and regulation of class switch recombination. Annu. Rev. Immunol. 26, 261-292 (2008).
15. Daniel JA, Nussenzweig A. The AID-induced DNA damage response in chromatin. Mol. Cell 50(3), 309-321 (2013).
16. Muramatsu M, Sankaranand VS, Anant S et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J. Biol Chem. 274(26), 18470-18476 (1999).
17. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102(5), 553-563 (2000).
18. Revy P, Muto T, Levy Y et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 102(5), 565-575 (2000)
19. Bransteitter R, Pham P, Scharff MD, Goodman MF. Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc. Natl Acad. Sci. USA 100(7), 4102-4107 (2003).
20. Chaudhuri J, Tian M, Khuong C, Chua K, Pinaud E, Alt FW. Transcription-targeted DNA deamination by the AID antibody diversification enzyme. Nature 422(6933), 726-730 (2003).
21. Dickerson SK, Market E, Besmer E, Papavasiliou FN. AID mediates hypermutation by deaminating single stranded DNA. J. Exp. Med. 197(10), 1291-1296 (2003).
22. Ramiro AR, Stavropoulos P, Jankovic M, Nussenzweig MC. Transcription enhances AID-mediated cytidine deamination by exposing single-stranded DNA on the nontemplate strand. Nat. Immunol. 4(5), 452-456 (2003).
23. Sohail A, Klapacz J, Samaranayake M, Ullah A, Bhagwat AS. Human activation-induced cytidine deaminase causes transcription-dependent, strand-biased C to U deaminations. Nucleic Acids Res. 31(12), 2990-2994 (2003).
24. Martin A, Scharff MD. Somatic hypermutation of the AID transgene in B and non-B cells. Proc. Natl Acad. Sci. USA 99(19), 12304-12308 (2002).
25. Mayorov VI, Rogozin IB, Adkison LR, Frahm C, Kunkel TA, Pavlov YI. Expression of human AID in yeast induces mutations in context similar to the context of somatic hypermutation at G-C pairs in immunoglobulin genes. BMC Immunol. 6, 10 (2005).
26. Yoshikawa K, Okazaki IM, Eto T et al. AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. Science 296(5575), 2033-2036 (2002).
27. Betz AG, Rada C, Pannell R, Milstein C, Neuberger MS. Passenger transgenes reveal intrinsic specificity of the antibody hypermutation mechanism: clustering, polarity, and specific hot spots. Proc. Natl Acad. Sci. USA 90(6), 2385-2388 (1993).
28. Golding GB, Gearhart PJ, Glickman BW. Patterns of somatic mutations in immunoglobulin variable genes. Genetics 115(1), 169-176 (1987).
29. Morgan HD, Dean W, Coker HA, Reik W, Petersen-Mahrt SK. Activation-induced cytidine deaminase deaminates 5-methylcytosine in DNA and is expressed in pluripotent tissues: implications for epigenetic reprogramming. J. Biol Chem. 279(50), 52353-52360 (2004).
30. Rogozin IB, Kolchanov NA. Somatic hypermutagenesis in immunoglobulin genes. II. Influence of neighbouring base sequences on mutagenesis. Biochim. Biophys. Acta 1171(1), 11-18 (1992).
31. Di Noia J, Neuberger MS. Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. Nature 419(6902), 43-48 (2002).
32. Imai K, Slupphaug G, Lee WI et al. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat. Immunol. 4(10), 1023-1028 (2003).
33. Rada C, Williams GT, Nilsen H, Barnes DE, Lindahl T, Neuberger MS. Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in UNGdeficient mice. Curr. Biol. 12(20), 1748-1755 (2002).
34. Cascalho M, Wong J, Steinberg C, Wabl M. Mismatch repair co-opted by hypermutation. Science 279(5354), 1207-1210 (1998).
35. Frey S, Bertocci B, Delbos F, Quint L, Weill JC, Reynaud CA. Mismatch repair deficiency interferes with the accumulation of mutations in chronically stimulated B cells and not with the hypermutation process. Immunity 9(1), 127-134 (1998).
36. Martomo SA, Yang WW, Gearhart PJ. A role for Msh6 but not Msh3 in somatic hypermutation and class switch recombination. J. Exp. Med. 200(1), 61-68 (2004).
37. Phung QH, Winter DB, Cranston A et al. Increased hypermutation at G and C nucleotides in immunoglobulin variable genes from mice deficient in the MSH2 mismatch repair protein. J. Exp. Med. 187(11), 1745-1751 (1998).
38. Rada C, Ehrenstein MR, Neuberger MS, Milstein C. Hot spot focusing of somatic hypermutation in MSH2-deficient mice suggests two stages of mutational targeting. Immunity 9(1), 135-141 (1998).
39. Wiesendanger M, Kneitz B, Edelmann W, Scharff MD. Somatic hypermutation in MutS homologue (MSH)3-, MSH6-, and MSH3/MSH6-deficient mice reveals a role for the MSH2-MSH6 heterodimer in modulating the base substitution pattern. J. Exp. Med. 191(3), 579-584 (2000).
40. Rada C, Di Noia JM, Neuberger MS. Mismatch recognition and uracil excision provide complementary paths to both Ig switching and the A/T-focused phase of somatic mutation. Mol. Cell 16(2), 163-171 (2004).
41. Shen HM, Tanaka A, Bozek G, Nicolae D, Storb U. Somatic hypermutation and class switch recombination in Msh6(-/-)Ung(-/-) double-knockout mice. J. Immunol. 177(8), 5386-5392 (2006).
42. Schrader CE, Guikema JE, Linehan EK, Selsing E, Stavnezer J. Activation-induced cytidine deaminase-dependent DNA breaks in class switch recombination occur during G1 phase of the cell cycle and depend upon mismatch repair. J. Immunol. 179(9), 6064-6071 (2007).
43. Han L, Masani S, Yu K. Overlapping activation-induced cytidine deaminase hotspot motifs in Ig class-switch recombination. Proc. Natl Acad. Sci. USA 108(28), 11584-11589 (2011).
44. Schmitz KM, Petersen-Mahrt SK. AIDing the immune system-DIAbolic in cancer. Semin. Immunol. 24(4), 241-245 (2012).
45. Vuong BQ, Lee M, Kabir S et al. Specific recruitment of protein kinase A to the immunoglobulin locus regulates classswitch recombination. Nat. Immunol. 10(4), 420-426 (2009).
46. Bardwell PD, Martin A, Wong E, Li Z, Edelmann W, Scharff MD. Cutting edge: the G-U mismatch glycosylase methyl-CpG binding domain 4 is dispensable for somatic hypermutation and class switch recombination. J. Immunol. 170(4), 1620-1624 (2003).
47. Di Noia JM, Rada C, Neuberger MS. SMUG1 is able to excise uracil from immunoglobulin genes: insight into mutation versus repair. EMBO J. 25(3), 585-595 (2006).
48. Doseth B, Ekre C, Slupphaug G, Krokan HE, Kavli B. Strikingly different properties of uracil-DNA glycosylases UNG2 and SMUG1 may explain divergent roles in processing of genomic uracil. DNA Repair (Amsterdam) 11(6), 587-593 (2012).
49. Ulrich HD. Regulating post-translational modifications of the eukaryotic replication clamp PCNA. DNA Repair (Amsterdam) 8(4), 461-469 (2009).
50. Arakawa H, Moldovan GL, Saribasak H, Saribasak NN, Jentsch S, Buerstedde JM. A role for PCNA ubiquitination in immunoglobulin hypermutation. PLoS Biol. 4(11), e366 (2006).
51. Delbos F, Aoufouchi S, Faili A, Weill JC, Reynaud CA. DNA polymerase eta is the sole contributor of A/T modifications during immunoglobulin gene hypermutation in the mouse. J. Exp. Med. 204(1), 17-23 (2007).
52. Diaz M, Verkoczy LK, Flajnik MF, Klinman NR. Decreased frequency of somatic hypermutation and impaired affinity maturation but intact germinal center formation in mice expressing antisense RNA to DNA polymerase zeta. J. Immunol. 167(1), 327-335 (2001).
53. Faili A, Aoufouchi S, Flatter E, Gueranger Q, Reynaud CA, Weill JC. Induction of somatic hypermutation in immunoglobulin genes is dependent on DNA polymerase iota. Nature 419(6910), 944-947 (2002).
54. Jansen JG, Langerak P, Tsaalbi-Shtylik A, Van Den Berk P, Jacobs H, De Wind N. Strand-biased defect in C/G transversions in hypermutating immunoglobulin genes in Rev1-deficient mice. J. Exp. Med. 203(2), 319-323 (2006).
55. Krijger PHL, Langerak P, Van Den Berk PCM, Jacobs H. Dependence of nucleotide substitutions on Ung2, Msh2, and PCNA-Ub during somatic hypermutation. J. Exp. Med. 206(12), 2603-2611 (2009).
56. Langerak P, Nygren AO, Krijger PH, Van Den Berk PC, Jacobs H. A/T mutagenesis in hypermutated immunoglobulin genes strongly depends on PCNAK164 modification. J. Exp. Med. 204(8), 1989-1998 (2007).
57. Roa S, Avdievich E, Peled JU et al. Ubiquitylated PCNA plays a role in somatic hypermutation and class-switch recombination and is required for meiotic progression. Proc. Natl Acad. Sci. USA 105(42), 16248-16253 (2008).
58. Zan H, Komori A, Li Z et al. The translesion DNA polymerase zeta plays a major role in Ig and bcl-6 somatic hypermutation. Immunity 14(5), 643-653 (2001).
59. Zeng X, Winter DB, Kasmer C, Kraemer KH, Lehmann AR, Gearhart PJ. DNA polymerase eta is an A-T mutator in somatic hypermutation of immunoglobulin variable genes. Nat. Immunol. 2(6), 537-541 (2001).
60. Ranjit S, Khair L, Linehan EK et al. AID binds cooperatively with UNG and Msh2-Msh6 to Ig switch regions dependent upon the AID C terminus. J. Immunol. 187(5), 2464-2475 (2011).
61. Vuong BQ, Herrick-Reynolds K, Vaidyanathan B et al. A DNA break-and phosphorylation-dependent positive feedback loop promotes immunoglobulin class-switch recombination. Nat. Immunol. 14(11), 1183-1189 (2013).
62. Navaratnam N, Morrison JR, Bhattacharya S et al. The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase. J. Biol Chem. 268(28), 20709-20712 (1993).
63. Anant S, Davidson NO. An AU-rich sequence element (UUUN[A/U]U) downstream of the edited C in apolipoprotein B mRNA is a high-affinity binding site for Apobec-1: binding of Apobec-1 to this motif in the 3 untranslated region of c-myc increases mRNA stability. Mol. Cell Biol. 20(6), 1982-1992 (2000).
64. Anant S, Murmu N, Houchen CW et al. Apobec-1 protects intestine from radiation injury through posttranscriptional regulation of cyclooxygenase-2 expression. Gastroenterology 127(4), 1139-1149 (2004).
65. Xie Y, Blanc V, Kerr TA et al. Decreased expression of cholesterol 7alpha-hydroxylase and altered bile acid metabolism in Apobec-1-/-mice lead to increased gallstone susceptibility. J. Biol Chem. 284(25), 16860-16871 (2009).
66. Petersen-Mahrt SK, Neuberger MS. In vitro deamination of cytosine to uracil in single-stranded DNA by apolipoprotein B editing complex catalytic subunit 1 (APOBEC1). J. Biol Chem. 278(22), 19583-19586 (2003).
67. Bishop KN, Holmes RK, Sheehy AM, Malim MH. APOBEC-mediated editing of viral RNA. Science 305(5684), 645 (2004).
68. Ikeda T, Ohsugi T, Kimura T et al. The antiretroviral potency of APOBEC1 deaminase from small animal species. Nucleic Acids Res. 36(21), 6859-6871 (2008).
69. Petit V, Guetard D, Renard M et al. Murine APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in vivo. J. Mol. Biol. 385(1), 65-78 (2009).
70. Gee P, Ando Y, Kitayama H et al. APOBEC1-mediated editing and attenuation of herpes simplex virus 1 DNA indicate that neurons have an antiviral role during herpes simplex encephalitis. J. Virol. 85(19), 9726-9736 (2011).
71. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418(6898), 646-650 (2002).
72. Bogerd HP, Cullen BR. Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. RNA 14(6), 1228-1236 (2008).
73. Khan MA, Kao S, Miyagi E et al. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol. 79(9), 5870-5874 (2005).
74. Schafer A, Bogerd HP, Cullen BR. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328(2), 163-168 (2004).
75. Svarovskaia ES, Xu H, Mbisa JL et al. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol Chem. 279(34), 35822-35828 (2004).
76. Yu Q, Konig R, Pillai S et al. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11(5), 435-442 (2004).
77. Harris RS, Bishop KN, Sheehy AM et al. DNA deamination mediates innate immunity to retroviral infection. Cell 113(6), 803-809 (2003).
78. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300(5622), 1112 (2003).
79. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424(6944), 99-103 (2003).
80. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424(6944), 94-98 (2003).
81. Weil AF, Ghosh D, Zhou Y et al. Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration. Proc. Natl Acad. Sci. USA 110(6), e448-e457 (2013).
82. Conticello SG, Harris RS, Neuberger MS. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13(22), 2009-2013 (2003).
83. Marin M, Rose KM, Kozak SL, Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9(11), 1398-1403 (2003).
84. Mehle A, Strack B, Ancuta P, Zhang C, Mcpike M, Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitinproteasome pathway. J. Biol Chem. 279(9), 7792-7798 (2004).
85. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9(11), 1404-1407 (2003).
86. Stopak K, De Noronha C, Yonemoto W, Greene WC. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12(3), 591-601 (2003).
87. Yu X, Yu Y, Liu B et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302(5647), 1056-1060 (2003).
88. Dang Y, Wang X, Esselman WJ, Zheng YH. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80(21), 10522-10533 (2006).
89. Delebecque F, Suspene R, Calattini S et al. Restriction of foamy viruses by APOBEC cytidine deaminases. J. Virol. 80(2), 605-614 (2006).
90. Zielonka J, Bravo IG, Marino D et al. Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases. J. Virol. 83(15), 7547-7559 (2009).
91. Hultquist JF, Lengyel JA, Refsland EW et al. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85(21), 11220-11234 (2011).
92. Harari A, Ooms M, Mulder LC, Simon V. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 83(1), 295-303 (2009).
93. Ohainle M, Kerns JA, Li MM, Malik HS, Emerman M. Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4(3), 249-259 (2008).
94. Tan L, Sarkis PT, Wang T, Tian C, Yu XF. Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J. 23(1), 279-287 (2009).
95. Liddament MT, Brown WL, Schumacher AJ, Harris RS. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14(15), 1385-1391 (2004).
96. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, Malim MH. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 83(18), 9474-9485 (2009).
97. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38(13), 4274-4284 (2010).
98. Li Q, Smith AJ, Schacker TW et al. Microarray analysis of lymphatic tissue reveals stage-specific, gene expression signatures in HIV-1 infection. J. Immunol. 183(3), 1975-1982 (2009).
99. Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1(1), e6 (2005).
100. Baumert TF, Rosler C, Malim MH, Von Weizsacker F. Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. Hepatology 46(3), 682-689 (2007).
101. Bonvin M, Achermann F, Greeve I et al. Interferoninducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43(6), 1364-1374 (2006).
102. Gunther S, Sommer G, Plikat U et al. Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G->A hypermutation. Virology 235(1), 104-108 (1997).
103. Kock J, Blum HE. Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. J. Gen. Virol. 89(Pt 5), 1184-1191 (2008).
104. Noguchi C, Hiraga N, Mori N et al. Dual effect of APOBEC3G on Hepatitis B virus. J. Gen. Virol. 88(Pt 2), 432-440 (2007).
105. Noguchi C, Imamura M, Tsuge M et al. G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection. J. Infect. Dis 199(11), 1599-1607 (2009).
106. Noguchi C, Ishino H, Tsuge M et al. G to A hypermutation of hepatitis B virus. Hepatology 41(3), 626-633 (2005).
107. Rosler C, Kock J, Malim MH, Blum HE, Von Weizsacker F. Comment on Inhibition of hepatitis B virus replication by APOBEC3G. Science 305(5689), 1403; author reply 1403 (2004).
108. Suspene R, Guetard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc. Natl Acad. Sci. USA 102(23), 8321-8326 (2005).
109. Turelli P, Mangeat B, Jost S, Vianin S, Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science 303(5665), 1829 (2004).
110. Vartanian JP, Henry M, Marchio A et al. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog. 6(5), e1000928 (2010).
111. Chen H, Lilley CE, Yu Q et al. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 16(5), 480-485 (2006).
112. Narvaiza I, Linfesty DC, Greener BN et al. Deaminaseindependent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog. 5(5), e1000439 (2009).
113. Vartanian JP, Guetard D, Henry M, Wain-Hobson S. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 320(5873), 230-233 (2008).
114. Wang Z, Wakae K, Kitamura K et al. APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation. J. Virol. 88(2), 1308-1317 (2014).
115. Tsuge M, Noguchi C, Akiyama R et al. G to A hypermutation of TT virus. Virus Res. 149(2), 211-216 (2010).
116. Huang CR, Burns KH, Boeke JD. Active transposition in genomes. Annu. Rev. Genet. 46, 651-675 (2012).
117. Koito A, Ikeda T. Intrinsic immunity against retrotransposons by APOBEC cytidine deaminases. Front. Microbiol. 4, 28 (2013).
118. Esnault C, Heidmann O, Delebecque F et al. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433(7024), 430-433 (2005).
119. Esnault C, Millet J, Schwartz O, Heidmann T. Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucleic Acids Res. 34(5), 1522-1531 (2006).
120. Schumacher AJ, Nissley DV, Harris RS. APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc. Natl Acad. Sci. USA 102(28), 9854-9859 (2005).
121. Bogerd HP, Wiegand HL, Doehle BP, Lueders KK, Cullen BR. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res. 34(1), 89-95 (2006).
122. Bogerd HP, Wiegand HL, Hulme AE et al. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc. Natl Acad. Sci. USA 103(23), 8780-8785 (2006).
123. Hulme AE, Bogerd HP, Cullen BR, Moran JV. Selective inhibition of Alu retrotransposition by APOBEC3G. Gene 390(1-2), 199-205 (2007).
124. Muckenfuss H, Hamdorf M, Held U et al. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol Chem. 281(31), 22161-22172 (2006).
125. Stenglein MD, Harris RS. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deaminationindependent mechanism. J. Biol Chem. 281(25), 16837-16841 (2006).
126. Chiu YL, Witkowska HE, Hall SC et al. High-molecularmass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl Acad. Sci. USA 103(42), 15588-15593 (2006).
127. Hiom K, Melek M, Gellert M. DNA transposition by the RAG1 and RAG2 proteins: a possible source of oncogenic translocations. Cell 94(4), 463-470 (1998).
128. Gourzi P, Leonova T, Papavasiliou FN. A role for activationinduced cytidine deaminase in the host response against a transforming retrovirus. Immunity 24(6), 779-786 (2006).
129. Macduff DA, Demorest ZL, Harris RS. AID can restrict L1 retrotransposition suggesting a dual role in innate and adaptive immunity. Nucleic Acids Res. 37(6), 1854-1867 (2009).
130. Metzner M, Jack HM, Wabl M. LINE-1 retroelements complexed and inhibited by activation induced cytidine deaminase. PLoS One 7(11), e49358 (2012).
131. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 16(1), 6-21 (2002).
132. Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. Science 293(5532), 1089-1093 (2001).
133. Law JA, Jacobsen SE. Establishing, maintaining and modifying DNA methylation patterns in plants and animals. Nat. Rev. Genet. 11(3), 204-220 (2010).
134. Mayer W, Niveleau A, Walter J, Fundele R, Haaf T. Demethylation of the zygotic paternal genome. Nature 403(6769), 501-502 (2000).
135. Oswald J, Engemann S, Lane N et al. Active demethylation of the paternal genome in the mouse zygote. Curr. Biol. 10(8), 475-478 (2000).
136. Santos F, Hendrich B, Reik W, Dean W. Dynamic reprogramming of DNA methylation in the early mouse embryo. Dev. Biol. 241(1), 172-182 (2002).
137. Hajkova P, Erhardt S, Lane N et al. Epigenetic reprogramming in mouse primordial germ cells. Mech. Dev. 117(1-2), 15-23 (2002).
138. Lee J, Inoue K, Ono R et al. Erasing genomic imprinting memory in mouse clone embryos produced from day 11.5 primordial germ cells. Development 129(8), 1807-1817 (2002).
139. Wu SC, Zhang Y. Active DNA demethylation: many roads lead to Rome. Nat. Rev. Mol. Cell Biol. 11(9), 607-620 (2010).
140. Pauklin S, Sernandez IV, Bachmann G, Ramiro AR, Petersen-Mahrt SK. Estrogen directly activates AID transcription and function. J. Exp. Med. 206(1), 99-111 (2009).
141. Rai K, Huggins IJ, James SR, Karpf AR, Jones DA, Cairns BR. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. Cell 135(7), 1201-1212 (2008).
142. Hendrich B, Hardeland U, Ng HH, Jiricny J, Bird A. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature 401(6750), 301-304 (1999).
143. Barreto G, Schafer A, Marhold J et al. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 445(7128), 671-675 (2007).
144. Schmitz KM, Schmitt N, Hoffmann-Rohrer U, Schafer A, Grummt I, Mayer C. TAF12 recruits Gadd45a and the nucleotide excision repair complex to the promoter of rRNA genes leading to active DNA demethylation. Mol. Cell 33(3), 344-353 (2009).
145. Liao W, Hong SH, Chan BH, Rudolph FB, Clark SC, Chan L. APOBEC-2, a cardiac-and skeletal muscle-specific member of the cytidine deaminase supergene family. Biochem. Biophys. Res. Commun. 260(2), 398-404 (1999).
146. Mikl MC, Watt IN, Lu M et al. Mice deficient in APOBEC2 and APOBEC3. Mol. Cell Biol. 25(16), 7270-7277 (2005).
147. Sato Y, Probst HC, Tatsumi R, Ikeuchi Y, Neuberger MS, Rada C. Deficiency in APOBEC2 leads to a shift in muscle fiber type, diminished body mass, and myopathy. J. Biol Chem. 285(10), 7111-7118 (2010).
148. Abdouni H, King JJ, Suliman M, Quinlan M, Fifield H, Larijani M. Zebrafish AID is capable of deaminating methylated deoxycytidines. Nucleic Acids Res. 41(10), 5457-5468 (2013).
149. Powell C, Elsaeidi F, Goldman D. Injury-dependent Muller glia and ganglion cell reprogramming during tissue regeneration requires Apobec2a and Apobec2b. J. Neurosci. 32(3), 1096-1109 (2012).
150. Vonica A, Rosa A, Arduini BL, Brivanlou AH. APOBEC2, a selective inhibitor of TGFbeta signaling, regulates left-right axis specification during early embryogenesis. Dev. Biol. 350(1), 13-23 (2011).
151. Bhutani N, Brady JJ, Damian M, Sacco A, Corbel SY, Blau HM. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature 463(7284), 1042-1047 (2010).
152. Bhutani N, Decker MN, Brady JJ et al. A critical role for AID in the initiation of reprogramming to induced pluripotent stem cells. FASEB J. 27(3), 1107-1113 (2013).
153. Kumar R, Dimenna L, Schrode N et al. AID stabilizes stem-cell phenotype by removing epigenetic memory of pluripotency genes. Nature 500(7460), 89-92 (2013).
154. Rai K, Sarkar S, Broadbent TJ et al. DNA demethylase activity maintains intestinal cells in an undifferentiated state following loss of APC. Cell 142(6), 930-942 (2010).
155. Popp C, Dean W, Feng S et al. Genome-wide erasure of DNA methylation in mouse primordial germ cells is affected by AID deficiency. Nature 463(7284), 1101-1105 (2010).
156. Santos F, Peat J, Burgess H, Rada C, Reik W, Dean W. Active demethylation in mouse zygotes involves cytosine deamination and base excision repair. Epigenetics Chromatin 6(1), 39 (2013).
157. Carpenter MA, Li M, Rathore A et al. Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. J. Biol Chem. 287(41), 34801-34808 (2012).
158. Wijesinghe P, Bhagwat AS. Efficient deamination of 5-methylcytosines in DNA by human APOBEC3A, but not by AID or APOBEC3G. Nucleic Acids Res. 40(18), 9206-9217 (2012).
159. Marchetto MCN, Narvaiza I, Denli AM et al. Differential L1 regulation in pluripotent stem cells of humans and apes. Nature 503(7477), 525-529 (2013).
160. Pastor WA, Aravind L, Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat. Rev. Mol. Cell Biol. 14(6), 341-356 (2013).
161. Tahiliani M, Koh KP, Shen Y et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324(5929), 930-935 (2009).
162. Guo JU, Su Y, Zhong C, Ming GL, Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145(3), 423-434 (2011).
163. Cortellino S, Xu J, Sannai M et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 146(1), 67-79 (2011).
164. Nabel CS, Jia H, Ye Y et al. AID/APOBEC deaminases disfavor modified cytosines implicated in DNA demethylation. Nat. Chem. Biol. 8(9), 751-758 (2012).
165. Rangam G, Schmitz KM, Cobb AJ, Petersen-Mahrt SK. AID enzymatic activity is inversely proportional to the size of cytosine C5 orbital cloud. PLoS One 7(8), e43279 (2012).
166. Millar CB, Guy J, Sansom OJ et al. Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice. Science 297(5580), 403-405 (2002).
167. Santos F, Dean W. Epigenetic reprogramming during early development in mammals. Reproduction 127(6), 643-651 (2004).
168. Cortazar D, Kunz C, Selfridge J et al. Embryonic lethal phenotype reveals a function of TDG in maintaining epigenetic stability. Nature 470(7334), 419-423 (2011).
169. Maiti A, Drohat AC. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. J. Biol Chem. 286(41), 35334-35338 (2011).
170. Hu XV, Rodrigues TM, Tao H et al. Identification of RING finger protein 4 (RNF4) as a modulator of DNA demethylation through a functional genomics screen. Proc. Natl Acad. Sci. USA 107(34), 15087-15092 (2010).
171. Hardeland U, Steinacher R, Jiricny J, Schr P. Modification of the human thymine-DNA glycosylase by ubiquitin-like proteins facilitates enzymatic turnover. EMBO J. 21(6), 1456-1464 (2002).
172. May A, Kirchner R, Muller H et al. Multiplex rt-PCR expression analysis of developmentally important genes in individual mouse preimplantation embryos and blastomeres. Biol. Reprod. 80(1), 194-202 (2009).
173. Ruddock-Dcruz NT, Xue J, Wilson KJ et al. Dynamic changes in the localization of five members of the methyl binding domain (MBD) gene family during murine and bovine preimplantation embryo development. Mol. Reprod. Dev. 75(1), 48-59 (2008).
174. Hajkova P, Jeffries SJ, Lee C, Miller N, Jackson SP, Surani MA. Genome-wide reprogramming in the mouse germ line entails the base excision repair pathway. Science 329(5987), 78-82 (2010).
175. Deans B, Griffin CS, Maconochie M, Thacker J. Xrcc2 is required for genetic stability, embryonic neurogenesis and viability in mice. EMBO J. 19(24), 6675-6685 (2000).
176. Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K. Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting. Science 265(5168), 103-106 (1994).
177. Tebbs RS, Flannery ML, Meneses JJ et al. Requirement for the Xrcc1 DNA base excision repair gene during early mouse development. Dev. Biol. 208(2), 513-529 (1999).
178. Pena-Diaz J, Jiricny J. Mammalian mismatch repair: error-free or error-prone? Trends Biochem. Sci. 37(5), 206-214 (2012).
179. Jaroudi S, Kakourou G, Cawood S et al. Expression profiling of DNA repair genes in human oocytes and blastocysts using microarrays. Hum. Reprod. 24(10), 2649-2655 (2009).
180. Menezo Y Jr, Russo G, Tosti E, El Mouatassim S, Benkhalifa M. Expression profile of genes coding for DNA repair in human oocytes using pangenomic microarrays, with a special focus on ROS linked decays. J. Assist. Reprod. Genet. 24(11), 513-520 (2007).
181. Liu M, Duke JL, Richter DJ et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature 451(7180), 841-845 (2008).
182. Honjo T, Kobayashi M, Begum N, Kotani A, Sabouri S, Nagaoka H. The AID dilemma: infection, or cancer? Adv. Cancer Res. 113, 1-44 (2012).
183. Incorvaia E, Sicouri L, Petersen-Mahrt SK, Schmitz KM. Hormones and AID. balancing immunity and autoimmunity. Autoimmunity 46(2), 128-137 (2013).
184. Beale RC, Petersen-Mahrt SK, Watt IN, Harris RS, Rada C, Neuberger MS. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J. Mol. Biol. 337(3), 585-596 (2004).